5′cytosine-Phospho-Guanine island methylation is responsible for p14ARF inactivation and inversely correlates with p53 overexpression in resected non-small cell lung cancer

Clinical Cancer Research

Volumn 10, Issue 14, 2004, Pages 4734-4741

  Hsu, Han Shui ^a   Wang, Yu Chien ^b   Tseng, Ruo Chia ^b   Chang, Jer Wei ^b   Chen, Jung Ta ^c   Shih, Chuen Ming ^d   Chen, Chih Yi ^c   Wang, Yi Ching ^b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN NORMAL UNIVERSITY   (Taiwan)

^c TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^d CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; PROTEIN P14ARF; PROTEIN P53; MICROSATELLITE DNA; PROTEIN P16INK4A;

ADENOCARCINOMA; ADULT; AGED; ALLELIC IMBALANCE; ARTICLE; CONTROLLED STUDY; CPG ISLAND; EPIGENETICS; FEMALE; GENE; GENE DELETION; GENE INACTIVATION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC ANALYSIS; HEMIZYGOSITY; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; METHYLATION; P14ARF GENE; P16INK4A GENE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DEPLETION; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; TUMOR SUPPRESSOR GENE; CHROMOSOME 9; DNA METHYLATION; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; HETEROZYGOSITY LOSS; HOMOZYGOTE; IMMUNOHISTOCHEMISTRY; LUNG TUMOR; METABOLISM; MIDDLE AGED; MUTATION; PATHOLOGY; SURVIVAL;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CHROMOSOMES, HUMAN, PAIR 9; CPG ISLANDS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA METHYLATION; FEMALE; GENE DELETION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HOMOZYGOTE; HUMANS; IMMUNOHISTOCHEMISTRY; LOSS OF HETEROZYGOSITY; LUNG NEOPLASMS; MALE; MICROSATELLITE REPEATS; MIDDLE AGED; MUTATION; PROGNOSIS; RNA, MESSENGER; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P14ARF; TUMOR SUPPRESSOR PROTEIN P53;

EID: 3242711153     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-03-0704     Document Type: Article

References (33)

1. Sherr CJ. The Pezcoller lecture: cancer cell cycles revised. Cancer Res 2000;60:3689-95.
2. Sharpless NE, DePinho RA. The INK4a/ARF locus and its two gene products. Curr Opin Genet Dev 1999;9:22-30.
3. Sherr CJ. Cancer cell cycles. Science 1996;274:1672-7.
4. Sherr CJ, Weber JD. The ARF/p53 pathway. Curr Opin Genet Dev 2000;10:94-9.
5. ARF, participates in a regulatory feedback loop with p53 and MDM2. EMBO J 1998;17:5001-14.
6. Quelle DE, Zindy F, Ashmun RA, Sherr CJ. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 1995;83:993-1000.
7. Arf induces p53-dependent apoptosis during abelson virus mediated pre-B cell transformation. Proc Natl Acad Sci (USA) 1998;95:13194-9.
8. Kamijo T, Zindy F, Roussel MF, et al. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell 1997;91:649-59.
9. Liggett WH, Sidransky D. Role of the p16 tumor suppressor gene in cancer. J Clin Oncol 1998;16:1197-206.
10. INK4A inactivation in non small-cell lung cancers. Oncogene 1998;16:497-504.
11. INK4a is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci (USA) 1998;95:11891-6.
12. 4a gene in resected non-small cell lung tumors and exfoliated cells within sputum. Int J Cancer 2002;98:724-31.
13. FitzGerald MG, Harkin DP, Silva-Arrieta S, et al. Prevalence of germ-line mutations in p16, p19ARF, and CDK4 in familial melanoma: analysis of a clinic-based population. Proc Natl Acad Sci USA 1996;9:8541-5.
14. Platz A, Hansson J, Mansson-Brahme E, et al. Screening of germ-line mutations in the CDKN2A and CDKN2B genes in Swedish families with hereditary cutaneous melanoma. J Natl Cancer Inst 1997;89:697-702.
15. Park MJ, Shimizu K, Nakano T, et al. Pathogenetic and biologic significance of TP14ARF alterations in nonsmall cell lung carcinoma. Cancer Genet Cytogenet 2003;141:5-13.
16. Gazzeri S, Della Valle V, Chaussade L, Brambilla C, Larsen CJ, Brambilla E. The human p19ARF protein encoded by the beta transcript of the p16INK4a gene is frequently lost in small cell lung cancer. Cancer Res 1998;58:3926-31.
17. Vonlanthen S, Heighway J, Tschan MP, et al. Expression of p16INK4a/p16α and p19ARF/p16β is frequently altered in non-small cell lung cancer and correlates with p53 overexpression. Oncogene 1998;17:2779-85.
18. Sanchez-Cespedes M, Reed AL, Buta M, et al. Inactivation of the INK4A/ARF locus frequently coexists with TP53 mutations in non-small cell lung cancer. Oncogene 1999;18:5843-9.
19. Gorgoulis VG, Zacharatos P, Kotsinas A, et al. Alterations of the p16-pRb pathway and the chromosome locus 9p21-22 in non-small-cell lung carcinomas: relationship with p53 and MDM2 protein expression. Am J Pathol 1998;153:1749-65.
20. ARF, p53, and p73 genes involved in the E2F-1-mediated apoptotic pathways in non-small cell lung carcinoma. Cancer Res 2001;61:5636-43.
21. Zöchbauer-Müller S, Pong KM, Virmani AK, Geradts J, Gazdar AF, Minna JD. 5′ Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res 200l;61:249-55.
22. INK4a methylation and p53 mutational status. Cancer Res 2000;60:129-33.
23. Kim DH, Kim JS, Ji YI, et al. Hypermethylation of RASSF1A promoter is associated with the age at starting smoking and a poor prognosis in primary non-small cell lung cancer. Cancer Res 2003;63:3743-6.
24. Wang YC, Chen CY, Chen SK, Cherng SH, Ho WL, Lee H. High frequency of deletion mutations in p53 gene from squamous cell lung cancer patients in Taiwan. Cancer Res 1998;58:328-33.
25. Sarkar S, Julicher KP, Burger MS, et al. Different combinations of genetic/epigenetic alterations inactivate the p53 and pRb pathways in invasive human bladder cancers. Cancer Res 2000;60:3862-71.
26. Weihrauch M, Markwarth A, Lehnen G, Wittekind C, Wrbitzky R, Tannapfel A. Abnormalities of the ARF-p53 pathway in primary angiosarcomas of the liver. Hum Pathol 2002;33:884-92.
27. ARF gene in gastric cancer. Int J Cancer 2000;87:654-8.
28. Yang Q, Nakamura M, Nakamura Y, et al. Two-hit inactivation of FHIT by loss of heterozygosity and hypermethylation in breast cancer. Clin Cancer Res 2002;8:2890-3.
29. Veigl ML, Kasturi L, O lechnowicz J, et al. Biallelic inactivation of hMLH1 by epigenetic gene silencing, a novel mechanism causing human MSI cancers. Proc Natl Acad Sci USA 1998;95:8698-702.
30. Toyoka S, Tsuda T, Gazdar AF. The TP53 gene, tobacco exposure, and lung cancer. Hum Mutat 2003;21:229-39.
31. Mitsudomi T, Hamajima N, Ogawa M, Takahashi T. Prognostic significance of p53 alterations in patients with non-small cell lung cancer: a meta-analysis. Clin Cancer Res 2000;6:4055-63.
32. Steels E, Paesmans M, Berghmans T, et al. Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. Eur Respir J 2001;18:705-19.
33. Xue Q, Sano T, Kashiwabara K, Saito M, Oyama T, Nakajima T. Aberrant expression of pRb, p16, p14ARF, MDM2, p21 and p53 in stage I adenocarcinomas of the lung. Pathol Int 2002;52:103-9.